



**Montana Medicaid Prior Authorization Request Form for Use of Viekira Pak<sup>®</sup>  
(ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets)**

**Viekira Pak<sup>®</sup> Initial Approval Form**

Patient's Name:	Patient's Medicaid ID#:
Patient's DOB:	Patient's Gender:
Provider's Name:	Provider's Specialty:
Provider's Phone #:	Provider's Fax #:
Today's Date:	Anticipated Viekira Pak <sup>®</sup> Start Date:

**I. Patient Readiness Evaluation:**

Patient psychosocial readiness is a critical component for Hepatitis C treatment success. It is important that any potential impediments to the effectiveness of treatment have been identified and that a plan for dealing with these impediments has been developed. The patient must be educated that abuse of alcohol may cause further liver damage and that abuse of IV injectable drugs will increase the risk of re-infection of Hepatitis C if the virus is cleared. Given the high cost of Hepatitis C treatment, we want to ensure that both the provider and the patient feel that the patient is committed to effectively start and successfully adhere to treatment. We highly recommend that you use a patient readiness evaluation tool such as Prep-C, a free interactive online tool which can be found at the following website: <https://prepc.org/>. **Please discuss the following questions with your patient, document their responses below, and have patient sign page 2:**

1. **Does patient have a history of alcohol abuse? Yes No**
  - If yes, how long has it been since patient last used alcohol?
  - If yes, is patient attending a support group or receiving counseling? Yes No
2. **Does patient have a history of injectable drug abuse? Yes No**
  - If yes, how long has it been since patient last used an injectable drug?
  - If yes, is patient attending a support group or receiving counseling? Yes No
3. **Does patient have a history of any other controlled-substance abuse? Yes No**
  - If yes, how long has it been since patient last used this substance?
  - If yes, is patient attending a support group or receiving counseling? Yes No
4. **Does patient have difficulties with medication compliance and/or showing up for appointments? Yes No**
  - If yes, how will compliance/ involvement be improved?
5. **Does patient have mental health conditions that are not being adequately treated? Yes No**
  - If yes, please explain, and state the plan for treatment:
6. **Does patient have adequate social support? Yes No**
  - If not, please state a plan to improve support:

## MT Medicaid Hepatitis C Patient Readiness Criteria:

1. Patient must not have a history of alcohol abuse, injectable drug abuse, and/or other controlled-substance abuse for at least 6 months prior to starting Hepatitis C treatment. Patient involvement in a support group or counseling is highly encouraged for successful abstinence.
2. Patient must be reasonably compliant with all current medications that are being prescribed for all disease states/conditions to be considered eligible for Hepatitis C treatment.
3. Patient must have a history of showing up for scheduled appointments/labs leading up to the prescribing of Hepatitis C treatment.
4. If patient has mental health conditions, patient must be compliant with mental health medications and/or psychotherapy. If patient has mental health conditions that are not currently being treated, then a mental health consult to assess for patient readiness will be required before Hepatitis C treatment can begin.

**Patient signature:** \_\_\_\_\_

**Date:** \_\_\_\_\_

## II. MT Medicaid Viekira Pak<sup>®</sup> Requirements:

**A. HCV genotype with subtyping (1a or 1b) (attach results):**

\_\_\_\_\_

**B. Pre-treatment hepatic function test result (ALT) and date lab was drawn (attach results). Note: Hepatic function lab testing will be required during the first 4 weeks of starting treatment and as clinically indicated thereafter if ALT elevation occurs.**

\_\_\_\_\_

**C. Documentation of extent of liver damage must be included [liver biopsy fibrosis stage (F0-F4), or any of the following non-invasive test results: APRI score, FibroSure score, or FibroScan results]**

\_\_\_\_\_

**D. Please provide Child-Pugh Classification Score (by points)-score each of 5 measures in table below to calculate total points: \_\_\_\_\_**

PARAMETER	Points Assigned		
	1	2	3
Ascites	Absent	Slight	Moderate
Bilirubin, total (mg/dL)	1.0-2.0	2.0-3.0	>3.0
Albumin (g/dL)	>3.5	2.8-3.5	<2.8
Prothrombin Time			
-Seconds prolonged	1.0-4.0	4.0-6.0	>6.0
-International normalized ratio (INR)	<1.7	1.7-2.3	>2.3
Encephalopathy*	None	Grade 1-2	Grade 3-4

\*Encephalopathy is classified as Grade 0 to 4:

**Grade**

0-no abnormality detected

1-shortened attention span, impaired addition and subtraction skills, mild euphoria or anxiety

2-Lethargy, apathy, disoriented to time, personality change, inappropriate behavior

3-Somnolence, semi-stupor, responsive to stimuli, confused when awake, gross disorientation

4-Coma, little or no response to stimuli, mental state not testable

Child Pugh Grade	Description	Total Points
A	Mild; well-compensated disease	5-6
B	Moderate; significant functional compromise	7-9
C	Severe; decompensated disease	10-15

**E. List any previously tried Hepatitis C treatments, dates treated, and response:**

---

**F. Patient must meet ALL of the following criteria\*:** (Please check all that apply)

- All chart notes related to Hepatitis C evaluation/treatment must be included
- Patient Readiness Evaluation (page 1) must be completed and patient must meet all of the Patient Readiness Criteria listed on page 2
- Documentation of extent of liver damage must be included (see page 2)
  - Individual is considered at highest risk for Hepatitis-C related complications (must have liver fibrosis staging of F3 or F4, be a liver transplant recipient, or have severe extrahepatic manifestations)
- Patient must not have decompensated cirrhosis (Child-Pugh Score C- see page 2)
- Diagnosis of chronic hepatitis C infection with HCV genotype 1a or 1b
- Patient is 18 years of age or older
- Must be prescribed by a gastroenterologist, infectious disease specialist, or a hepatologist.
- Patient does not have end stage renal disease requiring dialysis.
- Pre-treatment hepatic function test results (ALT) must be attached.
- Patient must not be taking any of the following medications (please circle if patient is taking): alfuzosin HCL, carbamazepine, phenytoin, phenobarbital, gemfibrozil, rifampin, ergotamine, dihydroergotamine, ergonovine, methylergonovine, ethinyl estradiol-containing medications (combined oral contraceptives, patches, or vaginal rings), St. John's Wort, lovastatin, simvastatin, pimozide, efavirenz, sildenafil when dosed for the tx of PAH, triazolam, orally administered midazolam.
- Patient must not have had previous treatment with telaprevir, boceprevir, simeprevir, sofosbuvir, or ledipasvir
- Patient must not have had treatment with any other Hepatitis C medications within the last 6 months
- If taking ribavirin, female patient or male patient's female partner must not be pregnant or planning to become pregnant during treatment or within 6 months after stopping treatment.

\*Any requests not meeting criteria will require review by the MT Medicaid DUR Board.

**G. Patient must meet ONE of these criteria, as well as ALL criteria listed above:** (Check the one that applies)

- HCV Genotype 1a, without cirrhosis:** Viekira Pak<sup>®</sup> + ribavirin for 12 weeks
- HCV Genotype 1a, with cirrhosis:** Viekira Pak<sup>®</sup> + ribavirin for 24 weeks\* (Note: Viekira Pak<sup>®</sup> + ribavirin for 12 wks may be considered for some pts based on prior treatment history)
- HCV Genotype 1b, without cirrhosis:** Viekira Pak<sup>®</sup> for 12 weeks
- HCV Genotype 1b, with cirrhosis:** Viekira Pak<sup>®</sup> + ribavirin for 12 weeks
- Liver Transplant Recipient with normal hepatic function and Metavir fibrosis score  $\leq 2$ :** Viekira Pak<sup>®</sup> + ribavirin for 24 weeks

**Limitations:**

1. Quantity Limit of **28 daily dose packs per 28 days** [Daily dose pack directions : two ombitasvir, paritaprevir, ritonavir 12.5/75/50 mg tablets once daily (in the morning) and one dasabuvir 250 mg tablet twice daily (morning and evening) with a meal.]
2. **Initial approval** will be granted for **4 weeks**.
3. Continuation of therapy beyond 4 weeks will require completion of **Viekira Pak<sup>®</sup> Renewal Form**. Note: Hepatic function tests (ALT) will need to be drawn within first 4 weeks of starting Viekira Pak<sup>®</sup>.

**Provider's Signature:** \_\_\_\_\_

**Date:** \_\_\_\_\_

**Please complete form, attach documentation, and fax to:  
Medicaid Drug Prior Authorization Unit at 1-800-294-1350**



**Montana Medicaid Prior Authorization Request Form for Use of Viekira Pak<sup>®</sup>**  
(ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets)

**Viekira Pak<sup>®</sup> Renewal Form**

Patient's Name:	Patient's Medicaid ID#:
Patient's DOB:	Patient's Gender:
Provider's Name:	Provider's Specialty:
Provider's Phone #:	Provider's Fax #:
Date:	

**Date Viekira Pak<sup>®</sup> was started:** \_\_\_\_\_

**Lab Requirements (attach lab results):**

- Pre-treatment ALT liver function test result and date lab was drawn: \_\_\_\_\_
- ALT result drawn within 4 wks after starting Viekira Pak<sup>®</sup> and date: \_\_\_\_\_

**HCV Genotype : (check one)**

- HCV Genotype 1a, without cirrhosis:** Viekira Pak<sup>®</sup> + ribavirin for 12 weeks
- HCV Genotype 1a, with cirrhosis:** Viekira Pak<sup>®</sup> + ribavirin for 24 weeks (Note: Viekira Pak<sup>®</sup> + ribavirin for 12 wks may be considered for some pts based on prior treatment history)
- HCV Genotype 1b, without cirrhosis:** Viekira Pak<sup>®</sup> for 12 weeks
- HCV Genotype 1b, with cirrhosis:** Viekira Pak<sup>®</sup> + ribavirin for 12 weeks
- Liver Transplant Recipient with normal hepatic function and Metavir fibrosis score  $\leq 2$ :** Viekira Pak<sup>®</sup> + ribavirin for 24 weeks

**Renewal Requirements:** The following requirement must be met: **(Please check)**

- Patient must have been **compliant** with Viekira Pak<sup>®</sup> as per protocol

**Renewal Limitations:**

- Quantity Limit of **28 daily dose packs per 28 days** [Daily dose pack directions : two ombitasvir, paritaprevir, ritonavir 12.5/75/50 mg tablets once daily (in the morning) and one dasabuvir 250 mg tablet twice daily (morning and evening) with a meal.]
- If patient meets criteria, Viekira Pak<sup>®</sup> will be approved as follows:
  - **HCV Genotype 1a, without cirrhosis:** Viekira Pak<sup>®</sup> + ribavirin will be authorized in 4 week increments (for a maximum total of 12 weeks)
  - **HCV Genotype 1a, with cirrhosis:** Viekira Pak<sup>®</sup> + ribavirin will be authorized in 4 week increments (for a maximum total of 24 weeks)
  - **HCV Genotype 1b, without cirrhosis:** Viekira Pak<sup>®</sup> will be authorized in 4 week increments (for a maximum total of 12 weeks)
  - **HCV Genotype 1b, with cirrhosis:** Viekira Pak<sup>®</sup> + ribavirin will be authorized in 4 week increments (for a maximum total of 12 weeks)
  - **Liver Transplant Recipient with normal hepatic function and Metavir fibrosis score  $\leq 2$ :** Viekira Pak<sup>®</sup> + ribavirin will be authorized in 4 week increments for a maximum total of 24 weeks

**Provider's Signature:** \_\_\_\_\_

**Date:** \_\_\_\_\_

**Please complete form, attach documentation, and fax to:  
Medicaid Drug Prior Authorization Unit at 1-800-294-1350**